Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Tofacitinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 known ✓ | P52333 | 19/20 | 1.00 |
| ▸ | JAK2 known ✓ | O60674 | 12/20 | 1.00 |
| ▸ | JAK1 known ✓ | P23458 | 11/20 | 1.00 |
| ▸ | TYK2 known ✓ | P29597 | 6/20 | 1.00 |
| ▸ | PKN2 | Q16513 | 4/20 | 1.00 |
| ▸ | ROCK2 | O75116 | 3/20 | 1.00 |
| ▸ | PRKCD | Q05655 | 3/20 | 1.00 |
| ▸ | STK3 | Q13188 | 3/20 | 1.00 |
| ▸ | ROCK1 | Q13464 | 3/20 | 1.00 |
| ▸ | CAMK2D | Q13557 | 3/20 | 1.00 |
| ▸ | LRRK2 | Q5S007 | 3/20 | 1.00 |
| ▸ | MARK3 | P27448 | 2/20 | 1.00 |
| ▸ | MARK2 | Q7KZI7 | 2/20 | 1.00 |
| ▸ | DCLK1 | O15075 | 2/20 | 1.00 |
| ▸ | ABL1 | P00519 | 2/20 | 1.00 |
| ▸ | LCK | P06239 | 2/20 | 1.00 |
| ▸ | FYN | P06241 | 2/20 | 1.00 |
| ▸ | RET | P07949 | 2/20 | 1.00 |
| ▸ | DMPK | Q09013 | 2/20 | 1.00 |
| ▸ | MAP4K2 | Q12851 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tofacitinib SCHEMBL1120705 | 1.00 | JAK3 (1.00) | JAK3JAK2JAK1TYK2PKN2 | |
| Tofacitinib SCHEMBL29816283 | 1.00 | JAK3 (1.00) | JAK3JAK2JAK1TYK2PKN2 | |
| Tofacitinib SCHEMBL11949309 | 1.00 | JAK3 (1.00) | JAK3JAK2JAK1TYK2PKN2 | |
| Tofacitinib SCHEMBL28416782 | 1.00 | JAK3 (1.00) | JAK3JAK2JAK1TYK2PKN2 | |
| Tofacitinib SCHEMBL23199919 | 1.00 | JAK3 (1.00) | JAK3JAK2JAK1TYK2PKN2 | |
| Tofacitinib SCHEMBL322753 | 1.00 | JAK3 (1.00) | JAK3JAK2JAK1TYK2PKN2 | |
| Tasocitinib SCHEMBL23058868 | 1.00 | JAK3 (1.00) | JAK3JAK2JAK1TYK2PKN2 | |
| Tasocitinib SCHEMBL30341861 | 1.00 | JAK3 (1.00) | JAK3JAK2JAK1TYK2PKN2 | |
| Tofacitinib SCHEMBL30925309 | 1.00 | JAK3 (1.00) | JAK3JAK2JAK1TYK2PKN2 | |
| SCHEMBL25703953 | 0.95 | JAK3 (0.91) | JAK3JAK2JAK1TYK2PKN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 11156 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4228644-B1 | N-[4-[1-(1,4-DIOXASPIRO[4.5]DEC-8-YL)-4-(8-OXA-3-AZABICYCLO[3.2.1]OCT-3-YL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-6-YL]PHENYL]-N'-METHYLUREA FOR USE IN THE TREATMENT OF COVID19 | NANTCELL INC (US) | 2026-05-27 | — | — | EP | claimed |
| EP-4746852-A1 | LIPID AGGREGATES FOR INTRAARTICULAR ADMINISTRATION | Universität Bern (CH) | 2026-05-27 | — | — | EP | claimed |
| WO-2026105679-A1 | PROPHYLACTIC AND/OR THERAPEUTIC AGENT FOR SKIN DISORDER | 国立大学法人神戸大学 | 2026-05-21 | — | — | WO | claimed |
| WO-2026107075-A1 | METHODS OF TREATING MULTIPLE SCLEROSIS WITH CD19-CD20 DUAL CAR-T CELLS | GENENTECH, INC. (US) | 2026-05-21 | — | — | WO | claimed |
| US-20260138973-A1 | SUBSTITUTED PYRIDINES FOR USE IN TREATING OR PREVENTING INFLAMMATORY DISEASES OR DISEASES ASSOCIATED WITH AN UNDESIRABLE IMMUNE RESPONSE | SITRYX THERAPEUTICS LTD (GB) | 2026-05-21 | — | — | US | claimed |
| US-20260137680-A1 | NOVEL COMPOUNDS | SITRYX THERAPEUTICS LTD (GB) | 2026-05-21 | — | — | US | claimed |
| WO-2026103922-A1 | CHIMERIC SHUTTLING RECEPTOR | 深圳市湾岛细胞科技有限公司 | 2026-05-21 | — | — | WO | claimed |
| US-20260137953-A1 | METHOD FOR TARGETED TREATING DERMATOSES | STRATA SKIN SCIENCES INC. (US) | 2026-05-21 | — | — | US | claimed |
| US-20260142011-A1 | PHARMACOKINETIC MODELING SYSTEMS FOR IMPROVED THERAPEUTIC DOSING | PROMETHEUS LABORATORIES INC (US) | 2026-05-21 | — | — | US | claimed |
| CN-122060073-A | Chimeric shuttle receptors | 深圳市湾岛细胞科技有限公司 | 2026-05-19 | — | — | CN | claimed |
| WO-2022022434-A1 | PHARMACEUTICAL COMPOSITION AND PREPARATION CONTAINING PHARMACEUTICALLY ACCEPTABLE SALT OF TOFACITINIB AND USE THEREOF | 杭州和正医药有限公司 | 2022-02-03 | — | — | WO | claimed |
| WO-2022022624-A1 | METHOD FOR PRODUCING CARDIOMYOCYTES BY MEANS OF REPROGRAMMING | 南京昕瑞再生医药科技有限公司 | 2022-02-03 | — | — | WO | claimed |
| WO-2022022369-A1 | SUSTAINED-RELEASE FORMULATION OF TOFACITINIB OR SALT THEREOF AND PREPARATION METHOD THEREFOR | 中国科学院上海药物研究所 | 2022-02-03 | — | — | WO | claimed |
| WO-2022023490-A1 | METHOD FOR TREATING IMMUNE TOXICITIES INDUCED BY IMMUNE CHECKPOINT INHIBITORS | ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS (FR) | 2022-02-03 | — | — | WO | claimed |
| EP-3944859-A1 | METHOD FOR TREATING IMMUNE TOXICITIES INDUCED BY IMMUNE CHECKPOINT INHIBITORS | Assistance Publique Hôpitaux de Paris (FR) | 2022-02-02 | — | — | EP | claimed |
| CN-113975280-A | Pharmaceutical composition containing pharmaceutically acceptable salt of tofacitinib, preparation and application | 杭州和正医药有限公司 | 2022-01-28 | — | — | CN | claimed |
| WO-2022016844-A1 | INTERFERON-BASED CANCER TREATMENT METHOD AND PHARMACEUTICAL COMPOSITION | 厦门特宝生物工程股份有限公司 | 2022-01-27 | — | — | WO | claimed |
| EP-3942045-A1 | A DBAIT MOLECULE IN COMBINATION WITH KINASE INHIBITOR FOR THE TREATMENT OF CANCER | ONXEO (FR) | 2022-01-26 | — | — | EP | claimed |
| EP-3685840-B1 | COMBINATIONS OF TOFACITINIB AND CRISABOROLE FOR USE IN TREATING INFLAMMATORY SKIN DISEASES | HEFEI INDUSTRIAL PHARMACEUTICAL INST CO LTD (CN) | 2022-01-26 | — | — | EP | claimed |
| CN-113952460-A | Compound external preparation for treating alopecia areata and preparation method thereof | 长沙晶易医药科技有限公司 | 2022-01-21 | — | — | CN | claimed |